Intra-Arterial Gemcitabine vs IV Gemcitabine PK Substudy in Patients with Locally Advanced Pancreatic Cancer Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium
https://renovorx.com/wp-content/uploads/2023/01/ASCO-GI-2023_Zuriekat-Agah_PK-Poster_Final.pdf
Incidence and Clinical Characteristics of Patients with LAPC and Mesenteric Vein Thrombosis and Current Treatment Paradigm Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium
https://renovorx.com/wp-content/uploads/2023/01/ASCO-GI_MVT-Poster.pdf
Toxicity and Efficacy of Stereotactic Body Radiation Therapy vs. Intensity-Modulated Radiation Therapy for the Treatment of Locally Advanced Pancreatic Cancer in a Phase 3 Trial Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium
https://renovorx.com/wp-content/uploads/2023/01/ASCO-GI_Radiation-Poster_KAG.pdf
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC): A Randomized Phase 3 Multicenter Study Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium
https://renovorx.com/wp-content/uploads/2023/01/ASCO-GI_Trials-in-Progress-Poster.pdf